knee osteoarthritis. Other primary gonarthrosis
Conditions
Interventions
Intervention 1: Intervention group 1: Elaeagnus angustifolia extract, capsule 200 mg (Barij Essence, Kashan), three times daily for 4 weeks. Intervention 2: Intervention group 2: Elaeagnus angustifoli
Treatment - Drugs
Intervention group 1: Elaeagnus angustifolia extract, capsule 200 mg (Barij Essence, Kashan), three times daily for 4 weeks
Intervention group 2: Elaeagnus angustifolia extract/Boswellia thurifera extract, capsule 200 mg/100 mg (Barij Essence, Kashan), three times daily for 4 weeks
Control group: Ibuprofen, capsule 400 mg (Barij Essence, Kashan), three times daily for 4 weeks
Sponsors
Barij Essence Pharmaceutical Company
Vice-Chancellor for research of Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age of 40 - 80 years; Osteoarthritis of at least one knee for at least 6 months based on the diagnostic criteria of American College of Rheumatology (ACR); Pain score > 40 mm based on the visual analogue scale (VAS); CRP serum level 7; Grade 2 or 3 of Kellgren-Laurence scale in knee radiography within the past 6 months Exclusion criteria: Dysfunction of either liver, kidneys, or cardiovascular system or malignancy; Use of intra-articular glucocorticoids within the past 3 months; Use of intra-articular sodium hyaluronate within the past 6 months; Use of systemic glucocorticoids (either oral or parenteral) within the past 3 months; Having other osteoarticular disorders (e.g., rheumatoid arthritis and gout); Uncontrolled hypertension (> 140/90 mm Hg); Increased ESR; Having gastric or duodenal ulcers (based on the medical history); Sensitivity to the intervention drug; Being candidate for arthroplasty surgery; Not use of the intervention drug for more than one week; Knee arthroscopy within the past 3 months; Illiteracy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lequesne's Pain and Function Index (LPFI). Timepoint: before the intervention and 4 weeks after the intervention. Method of measurement: Questionnaire.;Visual analogue scale (VAS). Timepoint: before the intervention and 4 weeks after the intervention. Method of measurement: scoring on the scale.;Patient global assessment (PGA). Timepoint: before the intervention and 4 weeks after the intervention. Method of measurement: scoring on the scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects. Timepoint: during the intervention. Method of measurement: patient report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRasool Soltani
Isfahan University of Medical Sciences
Outcome results
None listed